Research programme: Fc receptor modulators - Shire

Drug Profile

Research programme: Fc receptor modulators - Shire

Alternative Names: Anti-Fc gamma RIIb antibody - Shire; Anti-FcƴRIIb IgE; Anti-FcƴRIIb IgG; Anti-FcγRIIb antibody - Shire; Autoimmune disease therapy - Shire; sFcR - Shire; SM 201; SM 211; SM 301

Latest Information Update: 15 Jun 2016

Price : $50

At a glance

  • Originator SuppreMol
  • Developer Shire
  • Class Monoclonal antibodies
  • Mechanism of Action Fc gamma receptor IIB modulators; Fc receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders
  • Research Hypersensitivity

Most Recent Events

  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 04 Mar 2015 SuppreMol has been acquired by Baxter International
  • 10 Mar 2014 Early research in Hypersensitivity in Germany (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top